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Atrioventricular block can occur in normal children,
young adults or athletes. It is also associated with
underlying heart disease or occurs as a drug adverse
effect. Amphotericin B is used in the treatment of
invasive fungal infections. Cardiac toxicity is a rare
adverse reaction. We report the case of a 9-month girl,
admitted in the paediatric intensive care unit with
cytomegalovirus pneumonitis. During hospitalisation the
patient developed a systemic fungic infection and was
medicated with liposomal amphotericin B. On the third
day of treatment she began repeated episodes of
bradycardia with spontaneous reversion. The
investigation revealed a second-degree atrioventricular
block. We excluded the misplacement of the central
catheter, myocarditis or structural cardiomyopathy and
suspended amphotericin. After 8 days, the bradycardia
episodes ceased what was consistent with the drug’s
half-life. Amphotericin cardiotoxic mechanism is still
unclear. It may be related with alteration of myocardial
membrane depolarisation.
BACKGROUND
Bradycardia is defined as a heart rate below the
lowest normal values set for age. Although less
common in children than adults, it can occasionally
cause significant morbidity and sudden cardiac
death.1 The risk of death in untreated children with
complete block of the atrioventricular (AV) node is
5–8%.2 It is therefore important to identify chil-
dren at risk and who might benefit from thera-
peutic intervention. When an AV block is
identified, it is relevant to categorise it according to
the ECG findings. The conduction may be slowed
without missed beats (first degree), intermittent
with missed beats (second degree) or absent with
complete dissociation of the atrial and ventricular
activity (third degree). Wenckebach first described
the AV block as a progressive delay between atrial
and ventricular contraction with the eventual
failure of an atrial beat to reach the ventricle.3
Later, Mobitz divided the second-degree AV block
in type I (progressive PR interval prolongation that
precedes a non-conducted P wave) and type II (PR
interval unchanged before a non-conducted P
wave).4 Second-degree AV block usually does not
produce symptoms and can occur in normal chil-
dren and young adults or athletes.5 6 However, it is
also associated with an underlying heart disease
such as intrinsic AV nodal disease, structural cardio-
myopathy, myocarditis, endocarditis, acute inferior
myocardial infarction, after cardiac surgery, abla-
tion or catheterisation procedures and secondary to
hypothyroidism or hyperthyroidism.7 Impaired AV
conduction is also a recognised adverse reaction of
digitalis, calcium channel blockers, amiodarone,
adenosine and β-blockers.7 A variety of other drugs
can more rarely impair AV conduction.
Amphotericin B is a polyene antifungal agent
used as ‘gold standard’ in the treatment of invasive
fungal infections since the 1960s.8 The major
reasons for this lasting acceptance are its broad
spectrum and the relatively few examples of myco-
logical resistances to the drug.9 The main adverse
reactions associated with amphotericin are nephro-
toxicity, electrolyte abnormalities (hypokalaemia,
hypomagnesaemia and hyperchloremic acidosis),
infusion-related reactions (fever, nausea, vomiting,
chills, rigours) and normocytic, normochromic
anaemia.9 10 Lipid-based formulations of ampho-
tericin have been introduced in an attempt to
reduce the toxicities associated with amphotericin
B deoxycholate. On the basis of animal models and
clinical studies, these formulations reduce the risk




We report the case of a 9-month old girl,
ex-premature of 35 weeks, with a history of three
previous hospitalisations caused by uncomplicated
infections (fever without focus, acute bronchiolitis,
gastroenteritis) and failure to thrive since 6 months
of age. At the reported hospitalisation, she was
admitted at the emergency department with an
acute respiratory infection presented by malaise,
refusal to eat, tachypnoea and hypoxaemia. In view
of clinical deterioration with the developing of an
acute respiratory distress syndrome, she was trans-
ferred to the paediatric intensive care unit and was
mechanically ventilated. The investigation revealed
a cytomegalovirus (CMV) pneumonitis (positive
IgM serology plus bronchoalveolar lavage and
urine isolation of the virus). The immunological
investigation was negative. She was medicated with
ganciclovir, human unspecific immune globulin and
CMV-specific immunoglobulin. The patient began
gradual clinical recovery and was extubated from
mechanical ventilation. On the 14th day after
admission she began to have fever with increase of
the laboratory inflammatory parameters. The per-
ipheric and central line haemocultures were posi-
tive, with isolation of Candida parapsilosis. The
patient was medicated on the 16th day with liposo-
mal amphotericin B (3 mg/kg/day). The femoral
central line was removed and a right subclavian
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central line was placed. On the 18th day after admission she
began short-term episodes of bradycardia, all asymptomatic,
with spontaneous reversion to normal sinus rhythm (evolution
of episodes during hospitalisation represented in figure 1). The
remainder of the cardiovascular physical examination was
normal. Creatine kinase, troponin, calcium, potassium and mag-
nesium were between normal values. The ECG was normal and
the echocardiography did not show any evidence of myocarditis,
myocardial infarction or structural cardiomyopathy. This exam-
ination also revealed an intra-atrial position of the central cath-
eter (figure 2), which was then repositioned to an extra-cardiac
position (figure 3). A 24 h ECG monitoring (Holter examin-
ation) was performed and revealed a second degree atrioven-
tricular block, Mobitz type 1 alternating with Mobitz type 2
(figure 4). At this time, the patient was only medicated with
liposomal amphotericin B (third day of treatment) and with gan-
ciclovir (15th day of treatment). Liposomal amphotericin B was
suspended and the patient began fluconazole therapy. Along the
following 7 days the number of bradycardia episodes per day
diminished progressively (figure 1). Eight days after liposomal
amphotericin B interruption the episodes ended. We repeated
the 24 h ECG monitoring which was normal, without evidence
of any rhythm block.
OUTCOME AND FOLLOW-UP
In the 6 months follow-up after this hospitalisation the patient
did not repeat any episode of bradycardia or any cardiovascular
event. However, she was readmitted with another respiratory
infection. All immunological investigation till present date was
inconclusive.
DISCUSSION
In this case we report the diagnosis of adverse reaction to lipo-
somal amphotericin B, which was postulated after exclusion of
the main possible causes of bradycardia, in particular of second-
degree AV heart block. The major hypotheses considered in the
differential diagnosis were: viral myocarditis, misplacement of
the central venous catheter, structural cardiomyopathy, intrinsic
AV nodal disease and adverse pharmacological reaction.
On the basis of the patient medical history of recurrent infec-
tions and the confirmed CMV pneumonitis, we suspected that
our patient had a primary immunodeficiency. That led us to
consider viral myocarditis as a possible bradycardia aetiology.
The immunological investigation performed till the present date
was inconclusive. Nevertheless, there are also reports of CMV
myocarditis even in immunocompetent patients.13 14 However,
the combination of an asymptomatic patient with negative
cardiac enzymes and no suggestive evidence of myocarditis in
the ECG or the echocardiogram performed gave less consistency
to this hypothesis.
The misplacement of the subclavian vein catheter was con-
firmed by the echocardiogram performed that showed an
intra-atrial position of the central line. Cardiac dysrhythmias,
most often premature atrial or ventricular contractions are the
recognised complications during central venous access proce-
dures.15 16 These events are related with guidewire insertion
(the Seldinger technique) or catheter migration with patient
Figure 1 Graphic representation of
the bradycardia episodes along
hospitalisation. The blue line
represents the evolution of minimal
heart rate value and the red columns
represent the number of bradycardia
episodes per day since the 16th to the
37th days of hospitalisation (number of
the episodes in the top of each
column). Amphotericin therapy was
started on the 16th day and was
suspended on the 27th day of
hospitalisation.
Figure 2 First echocardiography. The white arrow points to the
central venous catheter tip located inside the right atrium.
Figure 3 Second echocardiography. No evidence of misplacement of
the central venous catheter after repositioning.
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movement with subsequent contact with the endocardium.
Although less frequently,16 right bundle branch blocks can also
occur, probably related to the bundle branch’s superficial pos-
ition in the right ventricular endocardium.8 This arrhythmias
and conduction abnormalities should resolve when the tip of
the catheter is pulled back a few centimetres.16 17 We reposi-
tioned our patient’s catheter and confirmed its extracardiac pos-
ition with echocardiography. Despite that, the patient continued
the bradycardia episodes.
There was also no evidence of a structural cardiomyopathy
noted in the echocardiograms performed. Since these bradycar-
dia episodes were stable (without signs of haemodynamic com-
promise) we did not perform an electrophysiological study to
exclude an intrinsic AV nodal disease before excluding a possible
pharmacological adverse reaction.
Cardiac toxicity is a rare adverse reaction associated with
amphotericin B.18–20 Ventricular arrhythmias and bradycardia
have been reported in acute overdoses but also with conven-
tional dosages and infusion rates.21 22 Electrolyte abnormalities
such as hypokalaemia and hypomagnesaemia related to ampho-
tericin B may play a role. However, case reports of arrhythmias
in patients with normal concentration of potassium and magne-
sium medicated with amphotericin suggest that it may be dir-
ectly cardiotoxic.9 23 Animal experiments have shown that
amphotericin B can result in prolongation of the PR interval,
prolongation of the action potential with decrease in its ampli-
tude.24–26 The drug mechanism of action is based on the
binding of the hydrophobic moiety of the amphotericin B mol-
ecule to the ergosterol present in fungal cell membrane, produ-
cing an aggregate that forms transmembrane channels. These
defects cause an increase in permeability to protons and mono-
valent cations with subsequent cytoplasmic leakage (mainly
potassium) that leads to fungal cell death.27 Despite the more
avid binding to ergosterol, amphotericin B also has the capacity
of binding to the cholesterol of mammalian cell membranes,
which is responsible for a major fraction of its toxic potential.28
Cardiac toxicity may be caused by the abolition of the slow
inward calcium channel current and alteration of membrane
depolarisation by the referred pores in the myocardial
membrane.20 26
In our patient, after the interruption of the liposomal ampho-
tericin B, the number of bradycardia episodes progressively
diminished along the following 7 days and stopped after 8 days.
The AV blockage resolution was confirmed with the 24 h ECG
monitoring performed 9 days after the drug suspension. This
evolution is consistent with the long terminal half-life of the
drug (152 h±116 h).29
There is no specific treatment for amphotericin B toxicity.
The drug is not removed by haemodialysis with conventional or
high-flux dialysis membranes.30 As the cardiac toxicity signs
become evident, after the suspension of amphotericin adminis-
tration the approach consists of supportive therapy directed at
correcting electrolyte abnormalities, anaemia and dialytic
support for renal failure. It is also important to exclude all
reversible causes of AV block and remove them. Transient pace-
maker placement is reserved to symptomatic or haemodynamic-
ally unstable patients.
Learning points
▸ Second-degree atrioventricular (AV) block may occur in
normal children, but it can be secondary to intrinsic cardiac
disease or be related with an adverse drug reaction.
All reversible causes should be excluded.
▸ Cardiac toxicity is a rare adverse reaction related to
liposomal amphotericin B. However, it should be considered
in a patient with recent bradycardia, AV block or ventricular
arrhythmias.
▸ There is no specific treatment for amphotericin B toxicity.
After the drug suspension, it is relevant to remember that
cardiac toxicity signs can persist for several days, consistent
with the long terminal half-life of the drug (152 h±116 h).
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